We analyzed 61 Life Sciences & BioTech tools based on their AI visibility across ChatGPT, Gemini, Claude, Perplexity, and Grok. The current leaders are Absci, Addition Therapeutics, Aerska Therapeutics. Here are the top-ranked Life Sciences & BioTech brands for 2026.
| Rank | Brand | AI Score | Tier | Trend |
|---|---|---|---|---|
| #1 | Absci | — | Growth | Stable |
| #2 | Addition Therapeutics | — | Emerging | Stable |
| #3 | Aerska Therapeutics | — | Emerging | Stable |
| #4 | Aevice Health | — | Emerging | Stable |
| #5 | Agomab Therapeutics | — | Emerging | Stable |
Absci is an AI drug creation company that combines generative AI with a synthetic biology platform t
Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP
Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzhei
Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that cont
Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontun
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-10
Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary
Beam Therapeutics develops precision genetic medicines using base editing technology that makes sing
$274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in
Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in pr
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial full
Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign weal
Cradle provides an AI platform for protein engineering that accelerates the design of improved enzym
Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bi
Raised $787M (Mar 2026) backed by Sanofi, Pfizer/Hillhouse, DST Global. $2.56B Sanofi collaboration.
FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ m
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks
Raised $107M Series B (Jan 2026) co-led by J&J Ventures and Google Ventures. EpiTAC targets membrane
Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis w
Raised $125M Series B (Jun 2025). First human cataract trials launching 2026. Oryom robot designed t
Gameto raised $70M Series B in 2024 for its stem cell technology that dramatically reduces IVF stimu
Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sut
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune c
Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938
Insitro integrates machine learning with high-throughput biology to discover and develop drugs faste
Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase
Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaust
Raised $48M Series A led by a16z Bio and GV (Feb 2026). YC-backed. Digital twins of human physiology
Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains
Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clini
Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPS
Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the ful
NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in A
Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrate
Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG505
Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollme
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fi
Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital,
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-20
Profluent uses AI to design novel proteins and gene editors, including the first AI-created CRISPR s
Raising $1B Series A at $5B valuation. Sam Altman-backed. Largest-funded pure-play longevity startup
$40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting patholog
Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to t
Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9
Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral mi
Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that c
Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLi
Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 fo
Raised $100M oversubscribed Series A (Apr 2026) co-led by RA Capital and a16z Bio. Novel ADC platfor
Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic
Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecifi
Raised $180M Series A (Jan 2025). CM313 achieved 95% response rate in treatment-refractory ITP in NE
Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA spl
Raised $175M Series B (Jan 2025) led by Hevolution, NEA, and Regeneron Ventures. First patient dosed
Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails tha
Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting
Positive 48-week Phase 2 BEHOLD data for UBX1325 in DME published in NEJM Evidence. Single-injection
Verdiva Bio raised $200M in 2025 for next-generation oral GLP-1 receptor agonists designed to match
Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming
Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and p
Based on our AI visibility analysis across ChatGPT, Claude, Gemini, Perplexity, and Grok, the top Life Sciences & BioTech tools in 2026 are Absci, Addition Therapeutics, Aerska Therapeutics. These rankings are based on how frequently each tool is recommended by AI systems.
We rank Life Sciences & BioTech tools by their AI Visibility Score, which measures how frequently and prominently each tool appears in answers from major AI platforms including ChatGPT, Claude, Gemini, Perplexity, and Grok. Higher scores mean more AI mentions and recommendations.
We currently track and analyze 61 Life Sciences & BioTech tools across all major AI platforms. Our database is updated regularly to reflect changes in AI recommendations and new market entrants.
Claim your brand profile to see full AI mention data, track your visibility score, and benchmark against competitors.
Track Your AI Visibility →